Literature DB >> 16242206

Surveillance of nosocomial infections in paediatric recipients of bone marrow or peripheral blood stem cell transplantation during neutropenia, compared with adult recipients.

H J Laws1, G Kobbe, D Dilloo, M Dettenkofer, R Meisel, R Geisel, R Haas, U Göbel, R Schulze-Röbbecke.   

Abstract

The aim of this prospective study was to analyse the incidence of nosocomial infections (NIs) during neutropenia after haematopoietic stem cell transplantation (HSCT) in paediatric and adult patients. Diagnosis of NI followed the modified surveillance protocol of the German National Reference Centre for Surveillance of NIs. During the 24-month study period, 38 and 39 transplantations were performed in paediatric and adult patients, respectively. Eighty percent and 92% of the paediatric and adult patients, respectively, underwent allogenic HSCT. In total, 1156 neutropenic days were documented. The incidence of NI during neutropenia in all recorded cases was 38.9 NI per 1000 days, without significant difference between the groups. No difference was found in the incidence rates of pneumonia, while there was a trend towards a higher incidence of bloodstream infection in adult patients. Significantly more episodes of fever of unknown origin were found in paediatric than adult patients. Pathogens were isolated in 19 of 45 cases of NI. Of the clinically documented infections, Gram-positive organisms were isolated in 79%, Gram-negative organisms were isolated in 16% and fungi were isolated in 5%. Surveillance of NI is an effective instrument to control the quality of health care. It should focus on device-associated infections or specific high-risk targets such as nosocomial pneumonia.

Entities:  

Mesh:

Year:  2005        PMID: 16242206     DOI: 10.1016/j.jhin.2005.05.010

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  6 in total

1.  Nosocomial infections and fever of unknown origin in pediatric hematology/oncology unit: a retrospective annual study.

Authors:  Youssef A Al-Tonbary; Othman E Soliman; Mohammed M Sarhan; Moustafa A Hegazi; Rasha A El-Ashry; Ashraf A El-Sharkawy; Osama S Salama; Raida Yahya
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

2.  Bloodstream infection in paediatric cancer centres--leukaemia and relapsed malignancies are independent risk factors.

Authors:  R A Ammann; H J Laws; D Schrey; K Ehlert; O Moser; D Dilloo; U Bode; A Wawer; A Schrauder; G Cario; A Laengler; N Graf; R Furtwängler; A Simon
Journal:  Eur J Pediatr       Date:  2015-03-26       Impact factor: 3.183

Review 3.  Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?

Authors:  Arne Simon; Rhoikos Furtwängler; Norbert Graf; Hans Jürgen Laws; Sebastian Voigt; Brar Piening; Christine Geffers; Philipp Agyeman; Roland A Ammann
Journal:  GMS Hyg Infect Control       Date:  2016-05-12

4.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

5.  Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland.

Authors:  Arne Simon; Roland A Ammann; Udo Bode; Gudrun Fleischhack; Hans-Martin Wenchel; Dorothee Schwamborn; Chara Gravou; Paul-Gerhardt Schlegel; Stefan Rutkowski; Claudia Dannenberg; Dieter Körholz; Hans Jürgen Laws; Michael H Kramer
Journal:  BMC Infect Dis       Date:  2008-05-23       Impact factor: 3.090

6.  Prospective study estimating healthcare associated infections in a paediatric hemato-oncology unit of a tertiary care hospital in North India.

Authors:  Ayush Gupta; Arti Kapil; S K Kabra; Rakesh Lodha; Seema Sood; Benu Dhawan; Bimal K Das; V Sreenivas
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.